Novo Nordisk's CagriSema emerges as strong competitor to Eli Lilly's Zepbound

Novo Nordisk's CagriSema is gaining attention as a potential competitor to Eli Lilly's Zepbound. Recent market corrections have made Novo Nordisk's stock more appealing to investors. Analysts expect strong financial results for Novo Nordisk by 2026. This outlook contrasts with previous assessments, highlighting a shift in market sentiment. Investors are advised to conduct thorough research before making any decisions. The article emphasizes the importance of understanding the risks involved in stock trading.